Upturn unsubscribed user
$1.14/ day, billed weekly
Cancel anytime
(Ad-Free, Unlimited access)​
NO CREDIT CARD REQUIRED
THRD
Upturn stock ratingUpturn stock rating

Third Harmonic Bio Inc. (THRD)

Upturn stock ratingUpturn stock rating
$5.43
Last Close (24-hour delay)
Profit since last BUY5.23%
upturn advisory
Consider higher Upturn Star rating
BUY since 50 days
  • BUY Advisory
  • SELL Advisory (Profit)​
  • SELL Advisory (Loss)​
  • Profit
  • Loss
  • Pass (Skip investing)
Upturn Stock infoUpturn Stock info Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • YEAR
  • MONTH
  • WEEK

Upturn Advisory Summary

06/30/2025: THRD (1-star) has a low Upturn Star Rating. Not recommended to BUY.

Upturn Star Rating

rating

Not Recommended Performance

These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.

Number of Analysts

rating

4 Analysts rated it

Limited analyst coverage, niche firm, research info may be scarce.

1 Year Target Price $3

1 Year Target Price $3

Analysts Price Target For last 52 week
$3Target price
Low$3.18
Current$5.43
high$16.02

Analysis of Past Performance

Type Stock
Historic Profit 26.55%
Avg. Invested days 39
Today’s Advisory Consider higher Upturn Star rating
Upturn Star Rating Upturn stock ratingUpturn stock rating
Upturn Advisory Performance Upturn Advisory Performance 4.0
Stock Returns Performance Upturn Returns Performance 3.0
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Upturn Profits based on simulationUpturn Profits based on simulation Last Close 06/30/2025

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 245.04M USD
Price to earnings Ratio -
1Y Target Price 3
Price to earnings Ratio -
1Y Target Price 3
Volume (30-day avg) 4
Beta 2.15
52 Weeks Range 3.18 - 16.02
Updated Date 06/29/2025
52 Weeks Range 3.18 - 16.02
Updated Date 06/29/2025
Dividends yield (FY) -
Basic EPS (TTM) -1.24

Earnings Date

Report Date -
When -
Estimate -
Actual -

Profitability

Profit Margin -
Operating Margin (TTM) -

Management Effectiveness

Return on Assets (TTM) -14.6%
Return on Equity (TTM) -19.94%

Valuation

Trailing PE -
Forward PE -
Enterprise Value -23565063
Price to Sales(TTM) -
Enterprise Value -23565063
Price to Sales(TTM) -
Enterprise Value to Revenue -
Enterprise Value to EBITDA -2.09
Shares Outstanding 45127800
Shares Floating 15603387
Shares Outstanding 45127800
Shares Floating 15603387
Percent Insiders 9.11
Percent Institutions 80.72

Analyst Ratings

Rating 2
Target Price 3
Buy -
Strong Buy 1
Buy -
Strong Buy 1
Hold 3
Sell -
Strong Sell -
Strong Sell -

ai summary icon Upturn AI SWOT

Third Harmonic Bio Inc.

stock logo

Company Overview

overview logo History and Background

Third Harmonic Bio, Inc. was founded in 2019 and is a clinical-stage biopharmaceutical company focused on developing a highly selective oral small-molecule inhibitor of KIT for the treatment of severe allergic diseases. It went public in September 2022. In December 2023, the company announced it will be acquired by Tourmaline Bio.

business area logo Core Business Areas

  • Pharmaceutical Development: Focuses on developing oral small-molecule therapeutics for allergic diseases, specifically targeting the KIT receptor.

leadership logo Leadership and Structure

The leadership team includes key executives in research and development, clinical operations, and business development. The organizational structure is typical of a clinical-stage biotech company, with a focus on drug development.

Top Products and Market Share

overview logo Key Offerings

  • THB001: THB001 is Third Harmonic Bio's lead product candidate, an oral KIT inhibitor being developed for chronic urticaria (CSU) and other allergic diseases. Market share data is not yet available as it is still in clinical trials. Competitors include Xolair (omalizumab) by Novartis and Genentech and other emerging therapies from companies like Allakos and Sanofi.

Market Dynamics

industry overview logo Industry Overview

The pharmaceutical industry focusing on allergic diseases is characterized by a growing prevalence of conditions like chronic urticaria and asthma, driving demand for novel therapies. It's a competitive landscape with established players and emerging biotech companies.

Positioning

Third Harmonic Bio aims to differentiate itself with its oral, highly selective KIT inhibitor, targeting a key driver of mast cell activation in allergic diseases. Their competitive advantage lies in the potential for improved efficacy and convenience compared to existing therapies.

Total Addressable Market (TAM)

The global chronic spontaneous urticaria (CSU) market is estimated to reach billions of dollars. Third Harmonic Bio's THB001, if approved, could capture a significant share of this market by offering a novel treatment option. Market size is est. $3B.

Upturn SWOT Analysis

Strengths

  • Novel oral KIT inhibitor with potential for improved efficacy
  • Strong scientific team with experience in drug development
  • Focus on a specific unmet medical need in allergic diseases

Weaknesses

  • Single product pipeline, creating vulnerability
  • Reliance on successful clinical trial outcomes
  • Limited commercialization experience as a small biotech company

Opportunities

  • Potential to expand THB001 into other allergic indications
  • Partnerships with larger pharmaceutical companies for commercialization
  • Positive clinical trial results leading to regulatory approval and market access

Threats

  • Clinical trial failures
  • Competition from established therapies and emerging competitors
  • Regulatory hurdles and delays
  • Changes to deal with Tourmaline Bio

Competitors and Market Share

competitor logo Key Competitors

  • SNY (Sanofi)
  • NVS (Novartis)
  • XOMA

Competitive Landscape

Third Harmonic Bio faces competition from established pharmaceutical companies with approved therapies for allergic diseases. Its advantage lies in a novel mechanism of action and oral administration, but it carries risks associated with clinical development.

Growth Trajectory and Initiatives

Historical Growth: The company's growth has been focused on advancing THB001 through clinical trials.

Future Projections: Future growth depends on the successful completion of clinical trials and potential commercialization of THB001. Analyst estimates will depend on the clinical trial results.

Recent Initiatives: Recent initiatives include advancing THB001 through Phase 1b trials and preparing for Phase 2 studies and agreeing to be acquired by Tourmaline Bio.

Summary

Third Harmonic Bio is a clinical-stage biopharmaceutical company developing a novel oral KIT inhibitor for allergic diseases. The company faces clinical trial risks, but the technology has the potential to gain market share by providing a more effective and convenient treatment option. The recent news that Tourmaline Bio will aquire the company means the stock price now reflects the price of the deal and the clinical trial risk has been eliminated for the shareholders. The recent private placement strengthens the balance sheet while advancing THB001 through trials.

Peer Comparison

Sources and Disclaimers

Data Sources:

  • Company Website
  • SEC Filings
  • Analyst Reports
  • Press Releases

Disclaimers:

The information provided is for informational purposes only and should not be considered investment advice. Market share data is based on available information and estimates. Clinical trial results are subject to change.

Upturn AI SummarizationUpturn AI Summarization AI Summarization is directionally correct and might not be accurate.

Upturn AI SummarizationUpturn AI Summarization Summarized information shown could be a few years old and not current.

Upturn AI SummarizationUpturn AI Summarization Fundamental Rating based on AI could be based on old data.

Upturn AI SummarizationUpturn AI Summarization AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.

About Third Harmonic Bio Inc.

Exchange NASDAQ
Headquaters San Francisco, CA, United States
IPO Launch date 2022-09-14
CEO & Director Ms. Natalie C. Holles
Sector Healthcare
Industry Biotechnology
Full time employees 31
Full time employees 31

Third Harmonic Bio, Inc., a biopharmaceutical company, focuses on the development of the medicine for the treatment of dermal, respiratory, and gastrointestinal inflammatory diseases. The company develops oral small-molecule inhibitors of KIT, a cell surface receptor that serves as the master regulator of mast cell function and survival. It also develops THB335, an oral small molecule KIT inhibitor for the treatment of mast cell-mediated inflammatory diseases, respiratory, and gastrointestinal conditions. It has a license agreement with Novartis Pharma AG. The company was formerly known as Project IGE, Inc. and changed its name to Third Harmonic Bio, Inc. in June 2019. Third Harmonic Bio, Inc. was incorporated in 2019 and is headquartered in San Francisco, California.